Exagen Inc. (XGN) Tops Q3 EPS by 29c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Exagen Inc. Reports Third Quarter 2022 Results
November 14, 2022 4:05 PM ESTSAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2022.
Third Quarter Highlights:
Total revenue of $14.7 million recognized in the third quarter of 2022. Our flagship AVISE® CTD test, including AVISE® Lupus, recognized revenue of $12.8 million in the third quarter of 2022.Delivered 35,569 AVISE CTD tests, including AVISE Lupus, in the third quarter of 2022, a 12% increase over the third quarter of 2021. Since the... More